Do you have to try metformin before Mounjaro?

Yes for type 2 diabetes: Horizon BCBS requires a documented trial of metformin of at least 90 days, or a documented reason it can't be used (["contraindication", "ASCVD", "heart_failure", "CKD"]).

How long does a Mounjaro approval last with Horizon BCBS?

Initial approvals last 12 months, and renewals are granted in 12-month periods.

What does Horizon BCBS require to renew Mounjaro?

Continuation eligible if patient has been treated with a preferred agent within the past 90 days (samples not approvable), or prescriber attests patient has been treated with a preferred agent within past 90 days and is at risk if therapy is discontinued.

How current is this information?

This page reflects Horizon BCBS's written policy as of May 11, 2026, last verified against the source document on June 5, 2026.

Does Horizon BCBS cover Mounjaro?

Mounjaro for Type 2 Diabetes

What Horizon BCBS requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered (preferred drug)

What you need to qualify

A1C of 6.5% or higher
Trial of metformin for at least 90 days, or a documented reason it can't be used (["contraindication", "ASCVD", "heart_failure", "CKD"])
Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

New Start — Preferred Agent (Mounjaro)

All of:

Diagnosis of type 2 diabetes
A1C >= 6.5% confirmed by lab test
Patient will NOT use the requested agent in combination with a DPP-4 containing agent
Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
Patient will NOT use the requested agent in combination with OTC weight management products or supplements that may increase GLP hormone
Patient does NOT have any FDA labeled contraindications to the requested agent
Patient age is within FDA labeling for the requested indication

Plus any one of:

Medication history of use in the past 90 days to an agent containing metformin or insulin
FDA labeled contraindication to BOTH metformin AND insulin
Diagnosis of type 2 diabetes with or at high risk for atherosclerotic cardiovascular disease, heart failure, and/or chronic kidney disease

Continuation of Therapy — Preferred Agent (Mounjaro)

All of:

Diagnosis of type 2 diabetes
A1C >= 6.5% confirmed by lab test
Patient will NOT use the requested agent in combination with a DPP-4 containing agent
Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
Patient will NOT use the requested agent in combination with OTC weight management products or supplements that may increase GLP hormone
Patient does NOT have any FDA labeled contraindications to the requested agent
Patient age is within FDA labeling for the requested indication

Plus any one of:

Patient has been treated with a preferred agent within the past 90 days (starting on samples is not approvable)
Prescriber states patient has been treated with a preferred agent within the past 90 days and patient is at risk if therapy with a preferred agent is discontinued

Documentation to bring

Documentation of type 2 diabetes diagnosis
Lab result confirming A1C >= 6.5%
Documentation of prior metformin or insulin use within past 90 days, OR documentation of FDA labeled contraindication to both metformin AND insulin, OR documentation of T2DM with/at high risk for ASCVD, heart failure, and/or CKD
Attestation that patient will not use requested agent in combination with a DPP-4 inhibitor
Attestation that patient will not use requested agent in combination with another GLP-1 receptor agonist
Attestation that patient will not use requested agent in combination with OTC weight management products or GLP-hormone-increasing supplements
Confirmation patient has no FDA labeled contraindications to the requested agent

Quantity limits

2.5 MG/0.5ML, 5 MG/0.5ML, 7.5 MG/0.5ML, 10 MG/0.5ML, 12.5 MG/0.5ML, 15 MG/0.5ML — 4 pens per 28 days

Approval and renewal

Initial approval: 12 months
Renewal: every 12 months
To renew, the plan looks for Continuation eligible if patient has been treated with a preferred agent within the past 90 days (samples not approvable), or prescriber attests patient has been treated with a preferred agent within past 90 days and is at risk if therapy is discontinued.

Not covered when

Concurrent use with DPP-4 containing agents
Concurrent use with another GLP-1 receptor agonist
Concurrent use with OTC weight management products (e.g., orlistat/Alli) or supplements that may increase GLP hormone (e.g., berberine, curcumin, taurine, ginseng, wild bitter gourd)
FDA labeled contraindications to the requested agent (personal or family history of MTC or MEN 2; prior serious hypersensitivity reaction)

Policy note: Fill limit of one GLP-1 agent and one strength per 28 days. Mounjaro is listed as a preferred agent. Non-preferred agents (Byetta/Exenatide and Victoza/liraglutide) require step therapy through TWO preferred agents. For continuation of therapy as a preferred agent, samples do not count as prior therapy. QL approval is up to 12 months; one-time approval for titration dose extensions or when replacing another GLP-1 agent/strength within QL but over fill limit.

Policy effective May 11, 2026 · verified June 5, 2026 · source: NJ_GLP-1_Agonists_PAQL_ProgSum.pdf

Why Mounjaro requests get denied by Horizon BCBS

Based on what this policy asks for. Fix these before the first submission.

Wrong brand for the diagnosis. Mounjaro and Zepbound are the same molecule with different approved uses; a request for Mounjaro under a diagnosis that matches Zepbound is routinely denied.
No recent A1C result on file.
No documented metformin trial (dose, dates, and outcome) or a stated reason it can't be used.

Frequently asked questions

Does Horizon BCBS cover Mounjaro?: Horizon BCBS covers Mounjaro for type 2 diabetes with prior authorization on Employer / Commercial Insurance.
Do you have to try metformin before Mounjaro?: Yes for type 2 diabetes: Horizon BCBS requires a documented trial of metformin of at least 90 days, or a documented reason it can't be used (["contraindication", "ASCVD", "heart_failure", "CKD"]).
How long does a Mounjaro approval last with Horizon BCBS?: Initial approvals last 12 months, and renewals are granted in 12-month periods.
What does Horizon BCBS require to renew Mounjaro?: Continuation eligible if patient has been treated with a preferred agent within the past 90 days (samples not approvable), or prescriber attests patient has been treated with a preferred agent within past 90 days and is at risk if therapy is discontinued.
How current is this information?: This page reflects Horizon BCBS's written policy as of May 11, 2026, last verified against the source document on June 5, 2026.